# Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer

> **NCT00202800** · PHASE2 · COMPLETED · sponsor: **Corewell Health West** · enrollment: 40 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine, Etoposide

## Key facts

- **NCT ID:** NCT00202800
- **Lead sponsor:** Corewell Health West
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** 2007-09
- **Final completion:** 2011-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-06-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00202800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00202800, "Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT00202800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*